vs

Side-by-side financial comparison of Lipocine Inc. (LPCN) and Glimpse Group, Inc. (VRAR). Click either name above to swap in a different company.

Glimpse Group, Inc. is the larger business by last-quarter revenue ($1.3M vs $1.1M, roughly 1.1× Lipocine Inc.). On growth, Glimpse Group, Inc. posted the faster year-over-year revenue change (-59.0% vs -67.2%).

Lipocine Inc is a clinical-stage biopharmaceutical company specializing in the development of hormone-based therapies. Its core product pipeline targets unmet medical needs in men's health, women's health, and liver disease, with primary operations and market focus in the United States. It prioritizes oral formulation innovation to improve patient treatment accessibility and adherence.

The Glimpse Group, Inc. is a specialized immersive technology firm focused on developing virtual reality (VR) and augmented reality (AR) solutions. It serves enterprise, education, healthcare, and entertainment segments, offering custom immersive experiences and software tools for clients across North America and select global markets.

LPCN vs VRAR — Head-to-Head

Bigger by revenue
VRAR
VRAR
1.1× larger
VRAR
$1.3M
$1.1M
LPCN
Growing faster (revenue YoY)
VRAR
VRAR
+8.2% gap
VRAR
-59.0%
-67.2%
LPCN

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
LPCN
LPCN
VRAR
VRAR
Revenue
$1.1M
$1.3M
Net Profit
$-1.2M
Gross Margin
60.7%
Operating Margin
-97.1%
Net Margin
-94.3%
Revenue YoY
-67.2%
-59.0%
Net Profit YoY
-233.0%
-4837.1%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LPCN
LPCN
VRAR
VRAR
Q4 25
$1.1M
$1.3M
Q3 25
$1.4M
Q3 24
$0
Q1 24
$7.6M
Net Profit
LPCN
LPCN
VRAR
VRAR
Q4 25
$-1.2M
Q3 25
$-1.0M
Q3 24
$-2.2M
Q1 24
$3.5M
Gross Margin
LPCN
LPCN
VRAR
VRAR
Q4 25
60.7%
Q3 25
72.1%
Q3 24
Q1 24
Operating Margin
LPCN
LPCN
VRAR
VRAR
Q4 25
-97.1%
Q3 25
-95.6%
Q3 24
Q1 24
42.3%
Net Margin
LPCN
LPCN
VRAR
VRAR
Q4 25
-94.3%
Q3 25
-73.9%
Q3 24
Q1 24
46.1%
EPS (diluted)
LPCN
LPCN
VRAR
VRAR
Q4 25
$-0.06
Q3 25
$-0.05
Q3 24
$-0.44
Q1 24
$0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LPCN
LPCN
VRAR
VRAR
Cash + ST InvestmentsLiquidity on hand
$5.2M
$3.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$14.5M
$15.3M
Total Assets
$17.0M
$16.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LPCN
LPCN
VRAR
VRAR
Q4 25
$5.2M
$3.3M
Q3 25
$5.6M
Q3 24
$3.7M
Q1 24
$3.1M
Stockholders' Equity
LPCN
LPCN
VRAR
VRAR
Q4 25
$14.5M
$15.3M
Q3 25
$16.2M
Q3 24
$19.1M
Q1 24
$24.0M
Total Assets
LPCN
LPCN
VRAR
VRAR
Q4 25
$17.0M
$16.0M
Q3 25
$18.3M
Q3 24
$20.7M
Q1 24
$25.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LPCN
LPCN
VRAR
VRAR
Operating Cash FlowLast quarter
$-9.8M
$-739.2K
Free Cash FlowOCF − Capex
$-747.3K
FCF MarginFCF / Revenue
-57.5%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LPCN
LPCN
VRAR
VRAR
Q4 25
$-9.8M
$-739.2K
Q3 25
$-1.3M
Q3 24
$-2.8M
Q1 24
$2.4M
Free Cash Flow
LPCN
LPCN
VRAR
VRAR
Q4 25
$-747.3K
Q3 25
$-1.3M
Q3 24
Q1 24
FCF Margin
LPCN
LPCN
VRAR
VRAR
Q4 25
-57.5%
Q3 25
-92.8%
Q3 24
Q1 24
Capex Intensity
LPCN
LPCN
VRAR
VRAR
Q4 25
0.6%
Q3 25
0.6%
Q3 24
Q1 24
Cash Conversion
LPCN
LPCN
VRAR
VRAR
Q4 25
Q3 25
Q3 24
Q1 24
0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LPCN
LPCN

Segment breakdown not available.

VRAR
VRAR

Software Services$1.2M90%
Other$124.4K10%

Related Comparisons